Overview
The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer
Eligibility
Inclusion Criteria:
- Advanced non-small cell lung cancer confirmed by histology or cytology
- HER2 insertion mutation-positive
- Failure with first-line standard chemotherapy
- with measurable lesions.
Exclusion Criteria:
- no measurable tumor lesions
- Patients received PD-1 or Pyrotinib before